Acino Pharma eyes Ukrainian expansion through acquisition of local drugmaker
Swiss drugmaker Acino Pharma (SIX: ACIN) has finally closed a deal for the purchase of the Ukrainian firm Pharma Start, Ukraine’s ninth largest pharmaceutical producer, reports The Pharma Letter’s local correspondent. Financial terms of the transaction were not disclosed.
According to Josten Davidsen, chief executive of Acino, the acquisition of Pharma Start will help Acino to start active expansion in the market of CIS countries, and in particular Belarus, Azerbaijan, Kazakhstan and Uzbekistan, as well as to strengthen its position in the Eastern European region.
According to Acino’s plans, Pharma Start should enter the top five of Ukrainian drugmakers, as well as to increase its revenue from the current 300 million euros ($341 million) to 1 billion euros a year by 2018-2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze